News
Connect's next move is to set up a meeting with the FDA to discuss rademikibart’s phase 3 regulatory path. But despite the trial win, investors seemed unimpressed, sending Connect’s stock down ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results